Literature DB >> 12766081

The urokinase/urokinase receptor system in retinal neovascularization: inhibition by A6 suggests a new therapeutic target.

Paul G McGuire1, Terence R Jones, Nicholas Talarico, Erin Warren, Arup Das.   

Abstract

PURPOSE: The objective of the study was to determine the role of urokinase (uPA) and the urokinase receptor (uPAR) in retinal angiogenesis, and whether loss of uPAR or the inhibition of uPA/uPAR interactions could suppress the extent of retinal neovascularization in an animal model of ischemic retinopathy.
METHODS: Retinal neovascularization was induced by exposing newborn mice to 75% oxygen on postnatal day 7 for 5 days, followed by exposure to room air on days 12 to 17. The expression of uPAR in the retina was investigated by RT-PCR and immunohistochemistry. The role of uPAR in ischemic retinopathy was investigated by quantitating the extent of retinal neovascularization in the uPAR(-/-) mouse. The effects of inhibiting the uPA/uPAR interaction on the development of retinal neovascularization were studied in this animal model with a uPA-derived peptide, A6. Animals were treated with an intraperitoneal injection of A6 at a dose of 5, 10, or 100 mg/kg once a day on days 12 to 16. Control animals included oxygen-exposed mice treated with similar amounts of PBS only on days 12 to 16. The effect of A6 on the expression of uPAR in the retina was examined by real-time RT-PCR.
RESULTS: The expression of uPAR mRNA was upregulated in experimental animals during the period of angiogenesis and was localized to endothelial cells in the superficial layers of the retina. The uPAR(-/-) mouse demonstrated normal retinal vascular development; however, the absence of functional uPAR resulted in a significant reduction in the extent of retinal neovascularization. Histologic analysis of mice treated with A6 peptide showed significant inhibition of retinal neovascularization, and the response was dose dependent. The RT-PCR analysis of the retinas of the A6-treated animals showed a greater than twofold decrease in uPAR expression.
CONCLUSIONS: Expression of the urokinase receptor uPAR is essential to the development of retinal neovascularization. Inhibition of the activity of uPAR suppresses retinal neovascularization, possibly through a reduction in cell-associated proteolytic activity, cell signaling, or cell-matrix adhesion necessary for cell migration during angiogenesis. The uPA/uPAR interaction may be an important therapeutic target in the management of proliferative retinopathies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12766081     DOI: 10.1167/iovs.02-1160

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  13 in total

1.  Identification and functional analysis of endothelial tip cell-enriched genes.

Authors:  Raquel del Toro; Claudia Prahst; Thomas Mathivet; Geraldine Siegfried; Joshua S Kaminker; Bruno Larrivee; Christiane Breant; Antonio Duarte; Nobuyuki Takakura; Akiyoshi Fukamizu; Josef Penninger; Anne Eichmann
Journal:  Blood       Date:  2010-08-12       Impact factor: 22.113

Review 2.  Novel targets against retinal angiogenesis in diabetic retinopathy.

Authors:  Shuang Wang; James K Park; Elia J Duh
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

3.  Plasminogen activator inhibitor-1 (PAI-1) facilitates retinal angiogenesis in a model of oxygen-induced retinopathy.

Authors:  Anupam Basu; Gina Menicucci; Joann Maestas; Arup Das; Paul McGuire
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-05-14       Impact factor: 4.799

4.  Suppression of retinal neovascularization with an antagonist to vascular endothelial cadherin.

Authors:  Deepti Navaratna; Joann Maestas; Paul G McGuire; Arup Das
Journal:  Arch Ophthalmol       Date:  2008-08

Review 5.  Urokinase and its receptors in chronic kidney disease.

Authors:  Guoqiang Zhang; Allison A Eddy
Journal:  Front Biosci       Date:  2008-05-01

6.  Inhibition of choroidal neovascularization in rats by the urokinase-derived peptide A6.

Authors:  Hyoung J Koh; Kenichiro Bessho; Lingyun Cheng; Dirk-Uwe Bartsch; Terence R Jones; Germain Bergeron-Lynn; William R Freeman
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-02       Impact factor: 4.799

7.  Blockade of VEGF-induced GSK/β-catenin signaling, uPAR expression and increased permeability by dominant negative p38α.

Authors:  Jinling Yang; Ruth B Caldwell; M Ali Behzadian
Journal:  Exp Eye Res       Date:  2012-04-30       Impact factor: 3.467

8.  A peptide inhibitor of the urokinase/urokinase receptor system inhibits alteration of the blood-retinal barrier in diabetes.

Authors:  Deepti Navaratna; Gina Menicucci; Joann Maestas; Ramprasad Srinivasan; Paul McGuire; Arup Das
Journal:  FASEB J       Date:  2008-06-16       Impact factor: 5.191

9.  Angiogenic expression profile of normal and neurofibromin-deficient human Schwann cells.

Authors:  Stacey L Thomas; George H De Vries
Journal:  Neurochem Res       Date:  2007-04-03       Impact factor: 4.414

Review 10.  Modulation of CD44 Activity by A6-Peptide.

Authors:  Malcolm Finlayson
Journal:  Front Immunol       Date:  2015-03-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.